Core Viewpoint - Aktis Oncology, Inc. has successfully closed its upsized initial public offering (IPO) of 17,650,000 shares at a price of $18.00 per share, with additional shares bringing total gross proceeds to approximately $365.4 million [1]. Company Overview - Aktis Oncology is a clinical-stage oncology company focused on targeted radiopharmaceuticals aimed at large patient populations, including those not served by existing technologies [4]. - The company's advanced pipeline program targets Nectin-4, utilizing a miniprotein radioconjugate platform designed to deliver radioisotopes selectively to tumors while minimizing side effects [4]. - Aktis' platform is isotope-agnostic, allowing for visualization and verification of target engagement with imaging isotopes before therapeutic exposure [4]. - The company has a strategic collaboration with Eli Lilly and Company to develop novel radioconjugates beyond its proprietary pipeline [4]. IPO Details - The IPO was completed on January 12, 2026, with the underwriters fully exercising their option to purchase an additional 2,647,500 shares, expected to close on January 14, 2026 [1]. - The total gross proceeds from the IPO, including the additional shares, are anticipated to be around $365.4 million before deducting underwriting discounts and commissions [1]. - Aktis' common stock began trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026 [1].
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares